Please assess the completion status of the following clinical trial:

Trial Title: Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients newly diagnosed with stage IV colorectal cancer and with defined microsatellite instability status before initiation of systemic immunotherapy.~* Trackable cancer-driver mutation in the primary tumor documented before initiation of chemotherapy.~* Zubrod performance status of 0 or 1.~* Patients have measurable disease according to RECIST version (v)1.1.~* Ability to understand and willing to sign a written informed consent.~Exclusion Criteria:~* Severe anemia (hemoglobin \[Hb\] \< 8 g/dL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-correlative (Specimen collection) (Type: None): Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).